Document registry — page 29
Every document the Institute has published, 1,631 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised, double-blind, placebo-controlled, phase 2 study of Liraglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Liraglutide in mash randomising 52 participants over 48 weeks. Primary result: Resolution in 39 % versus 9…
Low12 Apr 2024 -
Consultation on the format of the supplier dossier series: what a dossier contains, in what order, and what it declines to contain. The draft fixes a common structure so…
11 Apr 2024 -
Observational, phase 2 study of Ipamorelin in gastric emptying over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low11 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low10 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Dulaglutide in type 2 diabetes and chronic kidney disease over as stated in the parent protocol. The Institute holds no reported…
Very low09 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low08 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low07 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Pramlintide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Exenatide in cardiovascular randomising 91 participants over 6 months. Primary result: No significant…
Moderate04 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low04 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low04 Apr 2024 -
Randomised crossover, phase 1 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low02 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low01 Apr 2024 -
Consultation on the draft monograph for BPC-157. The draft records that the Institute identified no completed randomised controlled trial in humans reporting a clinical…
31 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low31 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low30 Mar 2024 -
Consultation on the draft monograph for Cagrilintide, which the assessment committee released for public comment before ratification. The draft grades the compound's…
29 Mar 2024 -
Consultation on the draft monograph for Glutathione, which the assessment committee released for public comment before ratification. The draft grades the compound's…
29 Mar 2024 -
Randomised, open-label, active-controlled, phase 3 study of Tirzepatide in type 2 diabetes randomising 1,444 participants over 52 weeks. Primary result: Superior…
High26 Mar 2024 -
Phase 1 ascending dose, phase 1 study of Lixisenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low24 Mar 2024 -
Single-arm open-label, phase 3 study of Semaglutide, oral in cardiovascular and type 2 diabetes over open-label extension of the parent trial. The Institute holds no…
Very low23 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of SS-31 (elamipretide) in hfpef randomising 71 participants over 4 weeks. Primary result: No significant…
Low22 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low22 Mar 2024 -
Phase 1 ascending dose, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low22 Mar 2024 -
Consultation on the draft monograph for Maridebart cafraglutide, which the assessment committee released for public comment before ratification. The draft grades the…
21 Mar 2024 -
Consultation on the draft of CEI-MS-02, which specifies the performance a determination must achieve for identity and states what the resulting figure does not…
21 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported…
Very low21 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Lixisenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low21 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity and type 2 diabetes randomising 1,210 participants over 68 weeks. Primary result…
High20 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Tirzepatide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low19 Mar 2024 -
Record of documents ratified in the 2024 Q1 assessment cycle.
18 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Tesamorelin in mash randomising 61 participants over 12 months. Primary result: Reduction in hepatic fat…
Low18 Mar 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low18 Mar 2024 -
Single-arm open-label, phase 2 study of SS-31 (elamipretide) in mitochondrial disease over open-label extension of the parent trial. The Institute holds no reported…
Very low18 Mar 2024 -
Randomised crossover, phase 1 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low18 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low17 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low16 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in type 1 diabetes (adjunct) over as stated in the parent protocol. The Institute holds no…
Very low16 Mar 2024 -
Randomised, double-blind, active-controlled, phase 3 study of Tirzepatide in type 2 diabetes randomising 1,879 participants over 40 weeks. Primary result: All three…
High15 Mar 2024
page 29 of 41